Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Theravance Biopharma, Inc. (TBPH : NSDQ)

• Company Description    Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.? Number of Employees: 97

• Price / Volume Information    Yesterday's Closing Price: $14.30 Daily Weekly Monthly 20 Day Moving Average: 527,745 shares Shares Outstanding: 50.36 (millions) Market Capitalization: $720.16 (millions) Beta: 0.05 52 Week High: $14.55 52 Week Low: $7.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.51% 8.57% 12 Week 34.65% 22.31% Year To Date 51.97% 29.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 901 GATEWAY BOULEVARD - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-808-6000 fax: - investor.relations@theravance.com http://www.theravance.com

• General Corporate Information    Officers Rick E Winningham - Chief Executive Officer Susannah Gray - Chairperson of the Board of Directors Aziz Sawaf - Senior Vice President and Chief Financial Officer Laurie S. Alsup - Director Eran Broshy - Director Peer Information Theravance Biopharma, Inc. (GSAC) Theravance Biopharma, Inc. (CASI) Theravance Biopharma, Inc. (ALCD.) Theravance Biopharma, Inc. (OMNN) Theravance Biopharma, Inc. (CGPI.) Theravance Biopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G8807B106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 50.36 Most Recent Split Date: (:1) Beta: 0.05 Market Capitalization: $720.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.46 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 59.58 PEG Ratio: - Price Ratios Price/Book: 3.18 Price/Cash Flow: - Price / Sales: 9.33 EPS Growth vs. Year Ago Period: 417.65% vs. Previous Quarter: 500.00% Sales Growth vs. Year Ago Period: 83.75% vs. Previous Quarter: 70.23% ROE 06/30/25 - 6.93 03/31/25 - -32.37 12/31/24 - -29.70 ROA 06/30/25 - 3.52 03/31/25 - -16.48 12/31/24 - -15.63 Current Ratio 06/30/25 - 6.70 03/31/25 - 4.77 12/31/24 - 5.02 Quick Ratio 06/30/25 - 6.70 03/31/25 - 4.77 12/31/24 - 5.02 Operating Margin 06/30/25 - 16.88 03/31/25 - -89.38 12/31/24 - -87.63 Net Margin 06/30/25 - 16.88 03/31/25 - -89.38 12/31/24 - -87.63 Pre-Tax Margin 06/30/25 - 51.91 03/31/25 - -74.08 12/31/24 - -69.30 Book Value 06/30/25 - 4.50 03/31/25 - 3.32 12/31/24 - 3.57 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©